The Asia Pacific coagulation market was valued at US$ 889.52 million in 2022 and is expected to reach US$1.67 billion by 2030; it is estimated to grow at a CAGR of 8.2% from 2022 to 2030.
Thus, the adoption of various organic and inorganic strategies by the key market players is expected to provide opportunities for the coagulation market growth during the forecast period.
According to an article published in the National Center for Biotechnology Information (NCBI), "Cardiovascular Health and Diseases in China 2022," cardiovascular diseases (CVD) are the cause of ~47% and ~44% of all deaths in rural and urban regions in China, respectively. In 2020, nearly 330 million patients are predicted to suffer from CVD in China. According to a research study published in The Lancet, CVDs cause ~4 million deaths each year in China. CVD patients have elevated levels of coagulation factors in their bodies. Hence, an upsurge in the prevalence of CVDs is fueling the growth of the coagulation market in China.
Based on disease indication, the Asia Pacific coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest Asia Pacific coagulation market share in 2022.
Based on type, the Asia Pacific coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Asia Pacific coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.
In terms of offering, the Asia Pacific coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Asia Pacific coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.
By technology, the Asia Pacific coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Asia Pacific coagulation market share in 2022.
By end user, the Asia Pacific coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Asia Pacific coagulation market share in 2022.
Based on country, the Asia Pacific coagulation market is categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific coagulation market in 2022.
F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San & Tic Ltd.Şti., Siemens Healthineers AG; Sysmex Corp; and Transasia Bio-Medicals Ltd are some of the leading companies operating in the Asia Pacific coagulation market.
Growing Organic and Inorganic Strategies by Key Market Players Fuel Asia Pacific Coagulation Market
Changing lifestyle habits and a growing geriatric population are among the major factors increasing the prevalence of blood disorders. Therefore, there is a growing demand for early diagnosis and treatment. Key players are taking several initiatives through various organic and inorganic strategies to enhance the quality of life of patient population.- In July 2020, Sysmex Corporation launched the Automated Blood Coagulation Analyzers CN-6500/CN-3500 in Japan. The analyzer measures blood coagulation and platelet aggregation parameters, as well as thrombosis and hemostasis parameters.
- In October 2021, Trivitron Healthcare launched a new line of coagulation analyzer products manufactured by Diagon Ltd in India.
- In June 2021, Trivitron Healthcare introduced NANO H5 and NANO H110, which help in monitoring diabetes, hemoglobin variations, and thalassemia.
- In February 2021, Siemens Healthineers and Sysmex Corporation renewed their agreement to supply, distribute, sell, and service hemostasis products across the world. The agreement also included an extension for multiple years. Further, Siemens Healthineers agreed to distribute Sysmex's automated blood coagulation analyzer, such as the CN-3000 and CN-6000.
- In July 2022, HORIBA Medical launched the latest Yumizen G800 and G1550 hemostasis analyzers, as well as a range of convenient ready-to-use reagents for common blood coagulation Offerings. With this expansion of its product line, HORIBA Medical now offers a comprehensive selection of hemostasis systems and advanced reagents for laboratories of all sizes and requirements.
Thus, the adoption of various organic and inorganic strategies by the key market players is expected to provide opportunities for the coagulation market growth during the forecast period.
Asia Pacific Coagulation Market Overview
The Asia Pacific coagulation market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The factors contributing to the market progress in this region include the rising geriatric population, increasing incidences of cardiovascular diseases, growing prevalence of bleeding disorders, development of distribution networks, and advancements in coagulation analyzers.According to an article published in the National Center for Biotechnology Information (NCBI), "Cardiovascular Health and Diseases in China 2022," cardiovascular diseases (CVD) are the cause of ~47% and ~44% of all deaths in rural and urban regions in China, respectively. In 2020, nearly 330 million patients are predicted to suffer from CVD in China. According to a research study published in The Lancet, CVDs cause ~4 million deaths each year in China. CVD patients have elevated levels of coagulation factors in their bodies. Hence, an upsurge in the prevalence of CVDs is fueling the growth of the coagulation market in China.
Asia Pacific Coagulation Market Segmentation
The Asia Pacific coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.Based on disease indication, the Asia Pacific coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest Asia Pacific coagulation market share in 2022.
Based on type, the Asia Pacific coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Asia Pacific coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.
In terms of offering, the Asia Pacific coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Asia Pacific coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.
By technology, the Asia Pacific coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Asia Pacific coagulation market share in 2022.
By end user, the Asia Pacific coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Asia Pacific coagulation market share in 2022.
Based on country, the Asia Pacific coagulation market is categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific coagulation market in 2022.
F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San & Tic Ltd.Şti., Siemens Healthineers AG; Sysmex Corp; and Transasia Bio-Medicals Ltd are some of the leading companies operating in the Asia Pacific coagulation market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific Coagulation Market - Key Industry Dynamics
5. Coagulation Market - Asia Pacific Market Analysis
6. Asia Pacific Coagulation Market - Revenue and Forecast to 2030 - by Disease Indication
7. Asia Pacific Coagulation Market - Revenue and Forecast to 2030 - by Type
8. Asia Pacific Coagulation Market - Revenue and Forecast to 2030 - by Offering
9. Asia Pacific Coagulation Market - Revenue and Forecast to 2030 - by Technology
10. Asia Pacific Coagulation Market - Revenue and Forecast to 2030 - by End User
11. Asia Pacific Coagulation Market - Country Analysis
12. Coagulation Market-Industry Landscape
13. Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Genrui Biotech Co Ltd
- Horiba Ltd.
- ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti.
- Siemens Healthineers AG
- Sysmex Corp
- Transasia Bio-Medicals Ltd
